Astellas has agreed to acquire Ogeda thereby gaining a Phase II drug, fezolinetant, for the treatment of hot flushes related to menopause in a deal worth €800 M (US$853 M). Fezolinetant is one of few neurokinin 3 (NK3) antagonists in development for which Ogeda announced promising results from a Phase IIa trial in early 2017. The indication affects a large percentage of menopausal women and represents a high unmet clinical need. Fezolinetant is a non-hormonal treatment and therefore is not associated with the risks of hormone replacement therapy such as certain cancers, stroke and thromboembolism.